Patent: 9,603,927
✉ Email this page to a colleague
Summary for Patent: 9,603,927
Title: | Combination therapies with anti-CD38 antibodies |
Abstract: | The present invention relates to combination therapies with anti-CD38 antibodies. |
Inventor(s): | Doshi; Parul (Spring House, PA) |
Assignee: | Janssen Biotech, Inc. (Horsham, PA) |
Application Number: | 14/629,941 |
Patent Claims: | see list of patent claims |
Details for Patent 9,603,927
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2039-02-26 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |